TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -PRESS RELEASE- WeedMD Inc. a federally licensed producer and distributor of cannabis, announced today that it is one of the licensed producers to have its products and strains included in the University Health Network's first-of-its-kind Medical Cannabis Real-World Evidence study. UHN is launching Canada-wide clinical trials studying cannabis use on chronic pain, issues with sleep, anxiety and depression. Participating patients can select medical cannabis products via the Medical Cannabis by Shoppers portal, and registered under the TruTrace Technologies’ medical cannabis verification program. Read UHN’s announcement here.
“Recognizing the importance of strain validation as cannabis products advance through Canada’s medical and pharmaceutical channels is paramount for building trust and accountability in our industry and we congratulate UHN, Shoppers and TruTrace on this breakthrough initiative,” said Angelo Tsebelis, CEO of WeedMD. “As the only producer with all its products registered under StrainSecure, we are proud to be included. Patients and their medical practitioners expect traceability, origin assurance and consistency in their medicine, particularly when used as a natural alternate for treating traumatic indications such as pain management – this study will present much needed evidence and we’re looking forward to the results.”
The study is led by Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital, a recognized leader in educating Canadians about chronic pain and the risk factors of opioids.
“Many partners came together to launch this initiative, and we are proud to work with industry leaders to further our ability to provide Canadians with safe, consistent, rigorously tested cannabis-based medication,” said Ken Weisbrod, pharmacist and vice president of business development/cannabis strategy for Shoppers Drug Mart.
